Halozyme Therapeutics, Inc. (HALO)
109.61
+1.89
(+1.75%)
USD |
NASDAQ |
Sep 02, 16:00
109.77
+0.16
(+0.15%)
After-Hours: 20:00
Halozyme Therapeutics Cash and Short Term Investments (Quarterly) : 231.00M for June 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 231.00M |
| March 31, 2026 | 318.62M |
| December 31, 2025 | 142.82M |
| September 30, 2025 | 701.96M |
| June 30, 2025 | 548.18M |
| March 31, 2025 | 747.92M |
| December 31, 2024 | 596.07M |
| September 30, 2024 | 666.31M |
| June 30, 2024 | 529.03M |
| March 31, 2024 | 463.45M |
| December 31, 2023 | 336.00M |
| September 30, 2023 | 483.28M |
| June 30, 2023 | 348.28M |
| March 31, 2023 | 275.61M |
| December 31, 2022 | 362.79M |
| September 30, 2022 | 265.58M |
| June 30, 2022 | 209.36M |
| March 31, 2022 | 786.14M |
| December 31, 2021 | 740.92M |
| September 30, 2021 | 815.92M |
| June 30, 2021 | 755.31M |
| March 31, 2021 | 764.31M |
| December 31, 2020 | 368.01M |
| September 30, 2020 | 346.71M |
| June 30, 2020 | 385.45M |
| Date | Value |
|---|---|
| March 31, 2020 | 368.18M |
| December 31, 2019 | 421.26M |
| September 30, 2019 | 238.00M |
| June 30, 2019 | 287.46M |
| March 31, 2019 | 328.72M |
| December 31, 2018 | 354.53M |
| September 30, 2018 | 364.37M |
| June 30, 2018 | 398.89M |
| March 31, 2018 | 433.69M |
| December 31, 2017 | 469.21M |
| September 30, 2017 | 316.92M |
| June 30, 2017 | 297.53M |
| March 31, 2017 | 178.98M |
| December 31, 2016 | 204.98M |
| September 30, 2016 | 221.05M |
| June 30, 2016 | 229.99M |
| March 31, 2016 | 238.64M |
| December 31, 2015 | 108.34M |
| September 30, 2015 | 123.72M |
| June 30, 2015 | 140.72M |
| March 31, 2015 | 128.50M |
| December 31, 2014 | 135.62M |
| September 30, 2014 | 134.46M |
| June 30, 2014 | 147.65M |
| March 31, 2014 | 164.49M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Incyte Corp. | 4.536B |
| AVITA Medical, Inc. | 11.14M |
| Neurocrine Biosciences, Inc. | 389.80M |
| Iovance Biotherapeutics, Inc. | 297.67M |
| Editas Medicine, Inc. | 211.64M |